Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Profit After Tax: 2022-2025

Historic Profit After Tax for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$8.2 million.

  • InMed Pharmaceuticals' Profit After Tax fell 1.58% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 19.81%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.49% down from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Profit After Tax is -$8.2 million, which was down 6.49% from -$7.7 million recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Profit After Tax high stood at -$7.7 million for FY2024, and its period low was -$18.6 million during FY2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Profit After Tax value was -$7.9 million (recorded in 2023), while the average stood at -$7.9 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Profit After Tax skyrocketed by 57.27% in 2023, and later declined by 6.49% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Profit After Tax (Yearly) stood at -$18.6 million in 2022, then soared by 57.27% to -$7.9 million in 2023, then rose by 3.12% to -$7.7 million in 2024, then declined by 6.49% to -$8.2 million in 2025.